Table 1 Comparison of COVID-19 characteristics among PLWH who died or survived
Variable | Level | Total (N = 255), n (%) | Discharge (N = 195), n (%) | Death (N = 60), n (%) | p |
|---|---|---|---|---|---|
^Age | Median | 46 (37–54) | 45 (36–52) | 51 (44–59) |  < 0.001 |
Age categories |  < 40 | 77 (30.2) | 68 (34.9) | 9 (15.0) | 0.003 |
|  | 40–50 | 83 (32.6) | 64 (32.8) | 19 (31.7) |  |
|  |  > 50 | 95 (37.2) | 63 (32.3) | 32 (53.3) |  |
Sex | Male | 74 (29.1) | 50 (25.8) | 24 (40.0) | 0.034 |
| Â | Female | 180 (70.9) | 144 (74.2) | 36 (60.0) | Â |
Smoker | No | 242 (94.9) | 190 (97.4) | 52 (86.7) | 0.003 |
| Â | Yes | 13 (5.1) | 5 (2.6) | 8 (13.3) | Â |
Hypertension | No | 145 (56.9) | 115 (59.0) | 30 (50.0) | 0.220 |
| Â | Yes | 110 (43.1) | 80 (41.0) | 30 (50.0) | Â |
Diabetes Mellitus | No | 180 (70.6) | 141 (72.3) | 39 (65.0) | 0.280 |
| Â | Yes | 75 (29.4) | 54 (27.7) | 21 (35.0) | Â |
Chronic Kidney Disease | No | 237 (92.9) | 183 (93.8) | 54 (90.0) | 0.390 |
| Â | Yes | 18 (7.1) | 12 (6.2) | 6 (10.0) | Â |
TB | No | 222 (87.1) | 172 (88.2) | 50 (83.3) | 0.330 |
| Â | Yes | 33 (12.9) | 23 (11.8) | 10 (16.7) | Â |
Congestive Heart Failure | No | 248 (97.3) | 191 (97.9) | 57 (95.0) | 0.360 |
| Â | Yes | 7 (2.7) | 4 (2.1) | 3 (5.0) | Â |
Acute kidney injury | No | 212 (83.1) | 170 (87.2) | 42 (70.0) | 0.002 |
| Â | Yes | 43 (16.9) | 25 (12.8) | 18 (30.0) | Â |
ARDS | No | 244 (95.7) | 187 (95.9) | 57 (95.0) | 0.720 |
| Â | Yes | 11 (4.3) | 8 (4.1) | 3 (5.0) | Â |
Shock | No | 248 (97.3) | 190 (97.4) | 58 (96.7) | 0.670 |
| Â | Yes | 7 (2.7) | 5 (2.6) | 2 (3.3) | Â |
Cough | No | 62 (24.3) | 46 (23.6) | 16 (26.7) | 0.630 |
| Â | Yes | 193 (75.7) | 149 (76.4) | 44 (73.3) | Â |
Fever | No | 153 (61.2) | 115 (60.2) | 38 (64.4) | 0.560 |
| Â | Yes | 97 (38.8) | 76 (39.8) | 21 (35.6) | Â |
Sore Throat | No | 226 (89.0) | 171 (87.7) | 55 (93.2) | 0.230 |
| Â | Yes | 28 (11.0) | 24 (12.3) | 4 (6.8) | Â |
Myalgia | No | 198 (77.6) | 150 (76.9) | 48 (80.0) | 0.620 |
| Â | Yes | 57 (22.4) | 45 (23.1) | 12 (20.0) | Â |
ARV therapy | No | 22 (11.5) | 17 (11.6) | 5 (11.1) | 1.000 |
| Â | Yes | 169 (88.5) | 129 (88.4) | 40 (88.9) | Â |
Viral load | Undetectable (< 50 copies) | 117 (78.0) | 87 (79.1) | 23 (20.9) | 0.593 |
Undetectable (< 50 copies) | 33 (22.0) | 30 (75.0) | 10 (25.0) |  | |
Unknown/missing | 105 | 85 | 20 | Â | |
*CD4 categories |  < 200 | 73 (36.9) | 48 (32.0) | 25 (52.1) | 0.021 |
|  | 200–499 | 83 (41.9) | 65 (43.3) | 18 (37.5) |  |
| Â | \(\ge\)500 | 42 (21.2) | 37 (24.7) | 5 (10.4) | Â |
*CD4 Count | Median (IQR) | 267 (141–457) | 296.5 (174–498) | 188 (72.5–337) | 0.004 |
Oxygen saturation | Median (IQR) | 93 (86–97) | 94 (90–98) | 86.5 (74.5–93) |  < 0.001 |
PaO2 | Median (IQR) | 8 (6.8–9.9) | 8.1 (6.9–9.9) | 7.3 (6.1–11.2) | 0.160 |
FiO2 | Median (IQR) | 21 (21–21) | 21 (21–21) | 21 (21–40) | 0.016 |
HGT | Median (IQR) | 7.4 (6–11.9) | 7.3 (5.7–12.7) | 7.9 (6.8–11.8) | 0.100 |
Creatinine | Median (IQR) | 74 (58–116) | 71 (55–100) | 101 (71–262) |  < 0.001 |
CRP | Median (IQR) | 145 (76–223) | 139 (70–207) | 204 (124–285) |  < 0.001 |
White Cell Count | Median (IQR) | 8.64 (6.56–11.16) | 7.93 (6.35–10.59) | 9.42 (7.8–13.32) | 0.002 |
Lymphocytes | Median (IQR) | 1.65 (1.22–2.20) | 1.68 (1.27–2.22) | 1.37 (0.9–1.855) | 0.031 |
Neutrophils | Median (IQR) | 5.62 (4.12–8.22) | 5.34 (3.97–7.70) | 7.3 (5.60–9.35) | 0.002 |
Platelets | Median (IQR) | 280 (221–374) | 287 (223–374) | 273 (207–369) | 0.480 |
HbA1c | Median (IQR) | 12.8 (11.2–14) | 12.9 (11.3–14.1) | 12.0 (10.4–13.4) | 0.038 |